SGT 53

N/A

Report date: 2026/04/30 20:00:20

Base Information

Drug NameSGT 53
Drug Alias Namep53-gene-therapy-SynerGeneTfRscFv-Liposome-p53 Complex
ClassificationCell and gene therapy > Gene therapy > Plasmid
Mechanisms of ActionApoptosis stimulantsTumor suppressor genes modulatorsGene transference +[4] 
TargetsTumor suppressor genesTumor protein p53
Therapy Area/IndicationsHigh-Grade GliomaPancreatic NeoplasmsCarcinoid Tumor +[9] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesTaiwan
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesSynergene Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesChildren'S National Research InstituteSynergene Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsHigh-Grade GliomaPancreatic NeoplasmsCarcinoid Tumor +[7] 
Inactive IndicationsGlioblastomaNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A